Campbell & CO Investment Adviser LLC Theravance Biopharma, Inc. Transaction History

Campbell & CO Investment Adviser LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$8.29 - $9.92 $237,740 - $284,485	28,678 Added 185.0%	44,180 $374,000
Q1 2024 May 10, 2024	BUY	$8.22 - $11.59 $127,426 - $179,668	15,502 New	15,502 $139,000
Q2 2022 Aug 09, 2022	SELL	$8.41 - $10.34 $211,091 - $259,534	-25,100 Closed	0 $0
Q1 2022 May 09, 2022	BUY	$8.33 - $12.96 $209,083 - $325,296	25,100 New	25,100 $240,000
Q4 2021 Feb 10, 2022	SELL	$7.42 - $11.05 $201,824 - $300,560	-27,200 Closed	0 $0
Q3 2021 Nov 10, 2021	BUY	$6.77 - $14.41 $184,144 - $391,952	27,200 New	27,200 $201,000
Q1 2020 Apr 29, 2020	SELL	$17.84 - $31.21 $159,275 - $278,642	-8,928 Closed	0 $0
Q4 2019 Jan 23, 2020	BUY	$16.12 - $25.89 $143,919 - $231,145	8,928 New	8,928 $231,000

122

47.3M

200

12.8K

Ticker TBPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,782,400
Market Cap $640M
Description
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...

Get notified when there are updates to the investment portfolio of Campbell & CO Investment Adviser LLC, based on Form 13F filings with the SEC.

Stay updated on Campbell & CO Investment Adviser LLC with notifications on news.